Ensysce Biosciences announced the Site Initiation Visit was completed for the PF614-201 study, ‘A Randomized, Double-Blind, Placebo-Controlled Crossover Study of PF614 on Analgesic Response in the Cold Pressor Test in Healthy Male Subjects’ to evaluate time of onset for PF614. The study is being conducted by Dr. George Atiee at Dr. Vince Clinical Research in Overland, KS.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ENSC:
- Ensysce Biosciences price target lowered to $7 from $9 at H.C. Wainwright
- Ensysce Biosciences to present clinical data at PAINWeek
- ENSC Upcoming Earnings Report: What to Expect?
- Ensysce Biosciences reports Q2 EPS (98c), consensus ($2.73)
- Ensysce Biosciences announces IRB approval of key study protocol
